Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1-Reference-Cited by-同舟云学术

Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1

Published:1997-02 Issue:1 Volume:16 Page:101-113
ISSN:0257-277X
Container-title:Immunologic Research
language:en
Short-container-title:Immunol Res

Author:

Ulyanova Tatiana,Blasioli Julie,Thomas Matthew L.

Publisher

Springer Science and Business Media LLC

Subject

Immunology

Link

http://link.springer.com/content/pdf/10.1007/BF02786326.pdf

Reference117 articles.

1. Trowbridge IS, Thomas ML: CD45: an emerging role as a pro- tein tyrosine phosphatase required for lymphocyte activation and development. Ann Rev Immunol 1994;12:85–116.

2. Thomas ML, Reynolds PJ, Chain A, Ben-Neriah Y, Trowbridge IS: B-cell variant of mouse T200 (Ly-5): evidence for alternative mRNA splicing. Proc Natl Acad Sci USA 1987;84:5360–5363.

3. Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H: Differ- ential usage of three exons gen- erates at least five different mRN As encoding human leukocyte com- mon antigens. J Exp Med 1987; 166:1548–1566.

4. Saga Y, Lee JS, Saraiya C, Boyse EA: Regulation of alternative splicing in the generation of iso-forms of the mouse Ly-5 (CD45) glycoprotein. Proc Natl Acad Sci USA 1990;87:3728–3732.

5. Chang H-L, Lefrancois L, Zarouk-ian MH, Esselman WJ: Devel- opmental expression of CD45 alternative exons in murine T cells. J Immunol 1991; 147:1687–1693.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure of PD1 and its mechanism in the treatment of autoimmune diseases;Cell Biochemistry and Function;2023-07-20

2. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma;IET Systems Biology;2023-06-05

3. Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators;Clinical Laboratory;2023

4. Enhancement of immune response of piglets to PCV-2 vaccine by porcine IL-2 and fusion IL-4/6 gene entrapped in chitosan nanoparticles;Research in Veterinary Science;2018-04

5. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation;Frontiers in Immunology;2016-12-12